The adoption and use of expensive artemisinin-based antimalarial therapies in the past few years is unprecedented but has not been matched by a similar increase in parasitological confirmation of malaria diagnoses. Targeted treatment is important, not only to limit unnecessary dispensing of antimalarial treatment but also to allow judicious use of these precious, life-saving medicines, for which the supply of raw materials is decreasing because of reduced cultivation of Artemisia annua.